Novo Nordisk: A Stock or a Snake Oil?

See, the so-called “Steer study” isn’t some noble scientific crusade. It’s a real-world data mess-a chaotic collage of patient anecdotes and half-baked statistics. And yet, Wall Street’s hucksters are already painting Novo as the next Warren Buffett in a lab coat. Eli Lilly (LLY)’s Zepbound, the other contender, got shafted in the headlines, but let’s not forget: It’s a dual-agonist beast with more power but less stomach for the ride. The question isn’t just which drug is better-it’s which one people will tolerate long enough to matter.








